Watson Pharmaceuticals announced that the company participated in the 12th batch of centralized procurement of national drugs. The product pentanedioquil hydrochloride injection is to be selected. The proposed price is 3.57 yuan/bottle. The procurement period is from the date of implementation to December 31, 2029. This variety is a selective anticholinergic drug, mainly used for administration before anesthesia, etc., and passed the generic drug consistency evaluation in January 2024. The proposed selection results are based on the final data of the Joint Procurement Office, and the relevant procurement agreement has not yet been signed.

Watson Pharmaceuticals announced that the company participated in the 12th batch of centralized procurement of national drugs. The product pentanedioquil hydrochloride injection is to be selected. The proposed price is 3.57 yuan/bottle. The procurement period is from the date of implementation to December 31, 2029. This variety is a selective anticholinergic drug, mainly used for administration before anesthesia, etc., and passed the generic drug consistency evaluation in January 2024. The proposed selection results are based on the final data of the Joint Procurement Office, and the relevant procurement agreement has not yet been signed.